Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Marathoners' hearts under the microscope: is that plaque dangerous?

NCT ID NCT07625488

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study follows 250 male endurance athletes who were part of an earlier study to see how their heart arteries have changed over time. Researchers will use CT scans and AI to examine plaque buildup and determine if it is stable and harmless or likely to cause heart attacks. The goal is to understand why some athletes develop calcium deposits in their heart arteries despite being very fit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could clarify whether high levels of endurance exercise cause dangerous or harmless plaque buildup in athletes' hearts.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to non-athletes or women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are invited from the established MARC cohort, which originally included 318 Caucasian, middle-aged (≥45 years) male amateur athletes recruited between 2012 and 2014. At baseline, athletes were eligible if they engaged in regular endurance exercise and were free of known cardiovascular disease. All participants underwent a comprehensive sports medical evaluation without abnormalities prior to enrollment. The initial exclusion criteria included inability to provide informed consent and medical conditions precluding participation in exercise testing or CT imaging.

Ages

45 years and older

Sex

Male participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Previous participation in the original MARC study (enrolled between 2012-2014). Exclusion Criteria: * Inability to provide written informed consent. * Not willing to receive information about potential incidental CT findings. * Concurrent participation in an interventional study targeting cardiovascular health. Additional exclusion criteria for CCTA: * Not willing to undergo CCTA with intravenous contrast. * History of severe allergic reaction to iodinated contrast agents. * Renal dysfunction (eGFR \< 30 mL/min/1.73 m²). Additional exclusion criteria for maximal exercise testing: * Absolute contraindications to maximal exercise testing as defined by institutional SOPs, including but not limited to: * Recent acute myocardial infarction (3-5 days) * Unstable angina * Uncontrolled arrhythmias with symptoms or hemodynamic compromise * Syncope * Active endocarditis * Acute myocarditis or pericarditis * Uncontrolled heart failure * Acute pulmonary embolus or pulmonary infarction * Lower extremity thrombosis * Suspected aortic dissection * Uncontrolled asthma * Pulmonary edema * Resting room-air oxygen saturation ≤ 85 percent * Respiratory failure * Acute non-cardiopulmonary disorders that impair or are aggravated by exercise (e.g., infection, renal failure, thyrotoxicosis) * Mental impairment preventing cooperation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder Genetic Risk Score inherited disease susceptibility Motor Activity Plaque, Atherosclerotic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Radboud University Medical Center

    Nijmegen, 6525 GA, Netherlands

  • University Medical Center Utrecht

    Utrecht, 3584 CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.